- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
CMS Moves Closer to Forced Disclosure Provision
Drug and device companies have just a month remaining to comment on a proposed rule that would require them to report all financial relationships with doctors.
As reported last year by MedPage Today and again Monday by the New York Times, the "Physician Payment Sunshine" provisions of the Affordable Care Act (ACA), require that drug, medical device, biologic, and medical equipment manufacturers that produce any products covered by Medicare or Medicaid or the Children's Health Insurance Program must report all payments made to doctors and hospitals.
The government will post the financial relationship information on a public website where patients and anyone else can check what ties to the medical industry a given doctor has.
The Centers for Medicare and Medicaid Services will accept comments on the proposal until Feb. 17, 2012, and will respond to them in a final rule to be published later this year.
Read the full story at:http://tinyurl.com/6motgc7
Source: MedPage Today
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
